An open label pilot study to investigate the effects of two preparations of hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) injected intramuscularly into the deltoid and upper thigh muscle during the state of hypocortisolaemia - Effects of 100mg Hydrocortisone injection into Deltoid & Thigh

The London Clinic0 sites8 target enrollmentApril 8, 2015

ConditionsAddison's Disease MedDRA version: 20.1Level: PTClassification code 10001130Term: Addison's diseaseSystem Organ Class: 10014698 - Endocrine disorders Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]

DrugsSolu-Cortef Hydrocortisone 100mg/ml

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Addison's Disease
Sponsor: The London Clinic
Enrollment: 8
Status: Active, not recruiting
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 8, 2015

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

The London Clinic

Eligibility Criteria

Inclusion Criteria

•1\. Age 18\-70 inclusive
•2\. Written informed consent obtained prior to any study related assessments/procedure being conducted.
•3\. Men \& Women with a BMI between 18\-30kg/m2
•4\. Addison’s disease or Bilateral Adrenalectomised patients with pre hydrocortisone cortisol level below 100nmol/L and ACTH greater than 50ng/L on screening visit
•5\. All patients must be stabilised on hydrocortisone with no change in dosage for 6 months, other than transient increases for concurrent illness.
•6\. Able to self\-inject into deltoid and thigh muscles following teaching at recruitment.
•7\. Female patients of child\-bearing potential must be willing to use an acceptable method of birth control/abstinence from the time consent is signed until 6 weeks after treatment is discontinued. Acceptable methods include: physical barrier (male or female condom, contraceptive sponges, diaphragms and cervical caps), contraceptive pill or patch, spermicidal method alongside a physical barrier or an intrauterine device (IUD). Abstinence is also acceptable if it falls in line with the patients’ usual lifestyle however it must be complete abstinence and not either; periodic, ovulation timed, symptothermal or withdrawal based. Those patients that utilise hormonal contraceptives must have used the same method for at least three months before additional barrier contraception (as described above). Patients of non\-child\-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

•1\. Patient on oestrogen based or mixed oral contraceptives unless willing to use alternate effective method of contraception
•2\. Patient on any forms of oral steroids other than hydrocortisone.
•3\. Any patient with secondary adrenal failure
•4\. Patients with a diagnosis of any disease or condition listed in Hydrocortisone 100mg/ml and Solu\-Cortef®’s as being contraindicated or precautionary for use
•5\. Patient with concurrent illness in the week preceding screening/study visit.
•6\. Patients must not have had an adrenal crisis in the week before screening
•7\. Patient with Nelson’s syndrome.
•8\. Participating in another IMP investigation
•9\. Patient taking any medications/substances that are known to interact with hydrocortisone e.g. CYP3A4 inhibitors
•10\. Patient is unable or unwilling to comply with the protocol.